BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.05 by 180 percent. The company reported quarterly sales of $156.413 million which beat the analyst consensus estimate of $151.123 million by 3.50 percent. This is a 7.48 percent increase over sales of $145.534 million the same period last year.